{"metadata":{"title":"3-Year Liver Cancer Risk Score Interpreter - v2.0","arkId":"ark:/99999/fk4474n87d","version":"","owner":"University of Michigan Medical School","description":"This object accepts a 3-Year Hepatocellular Cancer risk score as input and generates a recommendation depending on an individual's risk of developing liver cancer.","contributors":"Flynn AJ, Boisvert P, Bahulekar N","keywords":"liver cancer, hepatocellular cancer, risk","published":"yes","lastModified":1479399956223,"createdOn":1479334540067,"objectType":null,"citations":[{"citation_id":null,"citation_title":"Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score","citation_at":"https://www.ncbi.nlm.nih.gov/pubmed/21497551"}],"license":{"licenseName":"","licenseLink":""}},"inputMessage":"<rdf:RDF xmlns:ot=\"http://uofm.org/objectteller/#\"\n xmlns:rdf=\"http://www.w3.org/1999/02/22-rdf-syntax-ns#\">\n  <rdf:Description rdf:about=\"http://uofm.org/objectteller/inputMessage\">\n    <ot:noofparams>1</ot:noofparams>\n    <ot:params>\n      <rdf:Seq>\n        <rdf:li>risk</rdf:li>\n      </rdf:Seq>\n    </ot:params>\n  </rdf:Description>\n  <rdf:Description rdf:about=\"http://uofm.org/objectteller/noRisk/\">\n    <ot:datatype>FLOAT</ot:datatype>\n    <ot:min>0</ot:min>\n  </rdf:Description>\n</rdf:RDF>\n","outputMessage":"<rdf:RDF xmlns:ot=\"http://uofm.org/objectteller/\"\n  xmlns:rdf=\"http://www.w3.org/1999/02/22-rdf-syntax-ns#\">\n  <rdf:Description rdf:about=\"http://uofm.org/objectteller/outputMessage\">\n    <ot:returntype>STRING</ot:returntype>\n  </rdf:Description>\n</rdf:RDF>\n","payload":{"content":"from math import exp\nimport math\n\n# version 2.0\n\ndef interpretLiverCancerRisk(info):\n    risk = float(info['risk'])\n\n    output = ''\n\n    if risk < 0.2:\n        output = \"\"\"\n            <p style=\"font-weight: bold;\">\n            TREATMENT RECOMMENDATION: No antiviral treatment for Hepatitis B is indicated at this time.</p>\n\n            <p>MONITORING RECOMMENDATION: Every 3 to 6 months, monitor and reassess liver function (ALT),\n            Hepatitis B e Antigen status (HBeAG), and Hepatitis B DNA virus copy counts(HBV-DNA).</p>\n            </div>\n            \"\"\"\n    elif 0.2 <= risk < 1:\n        output = \"\"\"\n            <p style=\"font-weight: bold;\">\n            TREATMENT RECOMMENDATION: Consider a liver biopsy or a non-invasive liver\n            fibrosis assessment and, if moderate or greater inflammation or fibrosis are detected,\n            then treat Hepatitis B with one of two first-line oral antiviral medications,\n            Entecavir (1 mg tablet by mouth on an empty stomach daily for adults)\n            or Tenofovir (300mg tablet by mouth daily for adults)</p>\n\n            <p>MONITORING RECOMMENDATION: Every 3 to 6 months, monitor and reassess liver\n            function (ALT), Hepatitis B e Antigen status (HBeAG), and Hepatitis B DNA virus\n            copy counts (HBV-DNA).</p>\n            \"\"\"\n    elif 1 <= risk <= 30:\n        output = \"\"\"\n            <p style=\"font-weight: bold;\">\n            TREATMENT RECOMMENDATION: Antiviral treatment with Pegylated Interferon alpha-2a (PEG-INFa2a) is recommended.\n            The normal adult dose is 180 micrograms by injection every week for 48 weeks. Common side effects include flu-like symptoms,\n            headache, fatigue, muscle soreness, and hair loss.</p>\n\n            <p>MONITORING RECOMMENDATION: Monitor the impact and effectiveness of antiviral treatment\n            every month by reassessing liver function (ALT), Hepatitis B e Antigen status (HBeAG),\n            and Hepatitis B DNA virus copy counts (HBV-DNA). If improvements are apparent,\n            consider changing the monitoring frequency to every 3 months.</p>\n            \"\"\"\n\n    else:\n        output = \"\"\"\n            <p style=\"font-weight: bold;\">\n            ALERT: A 3 year risk of hepatocelluar cancer of more than 30% may indicate a problem\n            with the risk scoring calculation itself. Check all patient data and reassess\n            hepatocellular risk to confirm. Assuming that the risk is more than 30%,\n            which is very high, then antiviral treatment is highly recommended.</p>\n\n            <p style=\"font-weight: bold;\">\n            TREATMENT RECOMMENDATION: Antiviral treatment is recommended.</p>\n\n            <p>MONITORING RECOMMENDATION: Monitor the impact and effectiveness of antiviral treatment\n            every month by reassessing liver function (ALT), Hepatitis B e Antigen status (HBeAG),\n            and Hepatitis B DNA virus copy counts (HBV-DNA). If improvements are apparent,\n            consider changing the monitoring frequency to every 3 months.</p>\n            \"\"\"\n\n    return \"\"\"\n        <div class=\"interpretation\">\n        %s\n        </div>\n        \"\"\" % output\n","functionName":"interpretLiverCancerRisk","engineType":"Python"},"logData":"ProvenanceLogData: \n\t wasAttributedTo: 'null',\n\t wasGeneratedBy: 'null',\n\t wasAssociatedWith: 'Lib-Admin Lib-Admin',\n\t used: 'null',\n\t startedAtTime: Wed Nov 16 17:15:39 EST 2016,\n\t endedAtTime: Wed Nov 16 17:15:40 EST 2016","uri":"ark:/99999/fk4474n87d"}